Swiss Continence Foundation

The Swiss Continence Foundation is a non-profit organization founded in April 2011 with the goal of supporting and advancing research and further education in the field of Neuro-Urology and functional urology. A central issue of the foundation is the considerable improvement in the quality of patient care and in the patients’ quality of life. In addition, the foundation’s support in high-quality advanced training and education in the field of Neuro-Urology and functional urology is supposed to contribute to the distribution of the knowledge gained from research and science to physicians, nursing specialists and to the interested public.

In order to achieve these goals we depend on your financial support and would be very pleased to receive a donation.

Bank details of the Swiss Continence Foundation:
Aargauische Kantonalbank
Kaiserstrasse 8, CH-4310 Rheinfelden
IBAN: CH88 0076 1501 7999 1200 1
BIC/Swift: KBAGCH22XXX
Welcome

Dear Friends and Colleagues, Ladies and Gentlemen

It is our great honour and pleasure to invite you to attend the 3rd International Neuro-Urology Meeting, to be held in Zürich, Switzerland, from 28-30th August 2014.

Neurogenic urinary tract dysfunction is highly prevalent and affects the lives of millions of people worldwide. It has a major impact on quality of life and sexuality and, besides the debilitating manifestations for patients, it also imposes a substantial economic burden on every healthcare system. Neuro-Urology is now a well-established and highly regarded sub-speciality bridging the fields of both Neurology and Urology. The world’s leading experts in Neuro-Urology will provide an overview on this rapidly developing and exciting discipline. This unique meeting combines conventional lectures, panel discussions, live urodynamics and live surgery. Emphasis is placed on the interactive component. There will be many opportunities to exchange thoughts, experiences and ideas and also make new friendships.

Neuro-Urology needs outstanding young researchers and clinicians – they are our speciality’s future! Therefore, we are excited to announce the prestigious Swiss Continence Foundation Award of 10’000 Swiss francs which will be awarded to the best contribution from a young Neuro-Urology talent at the 3rd International Neuro-Urology Meeting.

In addition, we are delighted that the 3rd International Neuro-Urology Meeting will be dedicated to the distinguished career of Prof. Jean-Jacques Wyndaele, one of the fathers of modern Neuro-Urology, as he enters retirement.

We are extremely honoured to be organising the 3rd International Neuro-Urology Meeting and are looking forward to seeing you in Zürich.

Best regards

Ass. Prof. Thomas M. Kessler
Chairman Swiss Continence Foundation

Dr. Ulrich Mehnert
Vice-Chairman Swiss Continence Foundation
Meeting faculty

Prof. Gérard Amarenco, Hôpital Tenon, Pierre et Marie Curie Medical School, Paris, France
Ass. Prof. Apostolos Apostolidis, University of Thessaloniki, Thessaloniki, Greece
Ass. Prof. Mário A. Averbeck, Moinhos de Vento Hospital, Porto Alegre, Brazil
Prof. Bertil F. M. Blok, Erasmus Medical Center, University of Rotterdam, Rotterdam, the Netherlands
Prof. Guy Bogaert, Leuven University Hospital, Leuven, Belgium
Prof. David Castro-Diaz, University Hospital of the Canary Islands, Tenerife, Spain
Prof. Emmanuel Chartier-Kastler, Groupe Hospitalier Pitié-Salpêtrière, Pierre et Marie Curie Medical School, Paris, France
Prof. Francisco Cruz, Hospital de S. Joao and Faculty of Medicine of Porto, Porto, Portugal
Prof. Armin Curt, Balgrist University Hospital, Zürich, Switzerland
Prof. Prokar Dasgupta, King’s College and Guy’s Hospital, London, UK
Dr. Laetitia de Kort, University Medical Center Utrecht, Utrecht, the Netherlands
Prof. Giulio del Popolo, Careggi University Hospital, Florence, Italy
Prof. Pierre Denys, Raymond Poincaré University Hospital, Garches, France
Prof. Stefan de Wachter, Antwerp University Hospital, Antwerp, Belgium
Prof. Marcus J. Drake, University of Bristol, Bristol, UK
Dr. Sohier Elneil, University College Hospital and National Hospital for Neurology and Neurosurgery, London, UK
Dr. Daniel Engeler, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
Prof. Enrico Finazzi-Agrò, University of Rome Tor Vergata, Rome, Italy
Prof. Clare J. Fowler, Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK
Ass. Prof. Xavier Gamé, Rangueil University Hospital, Toulouse, France
Prof. Rita Gobet, University Children's Hospital Zürich, Zürich, Switzerland
Mr. Rizwan Hamid, University College London Hospitals and Spinal Injuries Centre, London, UK
Prof. John P. Heesakkers, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
Prof. Gilles Karsenty, University of Marseille, Marseille, France
Ass. Prof. Thomas M. Kessler, Balgrist University Hospital, Zürich, Switzerland
Dr. Gustav Kiss, University Hospital Innsbruck, Innsbruck, Austria
Prof. Helmut Madersbacher, University Hospital Innsbruck, Innsbruck, Austria
Dr. Ulrich Mehnert, Balgrist University Hospital, Zürich, Switzerland
Dr. Livio Mordasini, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
Dr. Jalesh N. Panicker, Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK
Prof. Jürgen Pannek, Swiss Paraplegic Center, Nottwil, Switzerland
Dr. Peter F. W. M. Rosier, University Medical Center Utrecht, Utrecht, the Netherlands
Prof. Ryuji Sakakibara, Toho University Sakura Medical Center, Chiba, Japan
Ass. Prof. Daniel Max Schmid, University Hospital Zürich, Zürich, Switzerland
Ass. Prof. Martin Schubert, Balgrist University Hospital, Zürich, Switzerland
Prof. Brigitte Schurch, University Hospital Lausanne, Lausanne, Switzerland
Prof. Martin E. Schwab, University of Zürich and Swiss Federal Institute of Technology Zürich, Zürich, Switzerland
Mr. Julian Shah, University College London Hospitals and Spinal Injuries Centre, London, UK
Prof. Karl-Dietrich Sievert, Eberhard Karls University Tübingen, Tübingen, Germany
Dr. Michele Spinelli, Niguarda Hospital, Milan, Italy
Prof. Manfred Stöhrer, University of Essen and Technical University of München, Murnau, Germany
Prof. Tullio Sulser, University Hospital Zürich, Zürich, Switzerland
Prof. Philip E. van Kerrebroeck, University Hospital Maastricht, Maastricht, the Netherlands
Prof. Gommert A. van Koeveringe, University Hospital Maastricht, Maastricht, the Netherlands
Prof. Jean-Jacques Wyndaele, Antwerp University Hospital, Antwerp, Belgium
08.30 – 12.00  WORKSHOP: Botulinum toxin A intradetrusor injections  
Tutors: Apostolos Apostolidis, Francisco Cruz, Prokar Dasgupta, Rizwan Hamid, Daniel Max Schmid, Brigitte Schurch

WORKSHOP: Sacral neuromodulation  
Tutors: Bertil F. M. Blok, Stefan de Wachter, Sohier Elneil, Daniel Engeler, Livio Mordasini, Michele Spinelli, Philip E. van Kerrebroeck

Live surgery: Karl-Dietrich Sievert

Workshop participation requires separate registration. Number of participants is limited.

12.00 - 13.00  Lunch break
13.00 – 13.10  Welcome
Stefan de Wachter, Thomas M. Kessler

13.10 – 15.10  Neuro-physiology of lower urinary tract, sexual and bowel (dys)function
Panel: Apostolos Apostolidis, Bertil F. M. Blok, Armin Curt, Ryuji Sakakibara, Brigitte Schuch, Martin E. Schwab

Key aspects: Central and peripheral control, biochemical and structural alterations, from bench to bedside

15.10 - 15.40  Tea break

15.40 - 18.00  Diagnostics for neurogenic lower urinary tract, sexual and bowel dysfunction
Panel: Gérard Amarenco, Enrico Finazzi-Agrò, John P. Heesakkers, Peter F. W. M. Rosier, Martin Schubert, Gommert A. van Koeversinge, Jean-Jacques Wyndaele

Key aspects: Bladder diary, medical history, clinical examination, blood samples, sonography, urodynamics, neuro-physiology

LIVE URODYNAMICS
08.30 – 10.00  **Neuro-Urology in children and adolescents**  
Panel: Guy Bogaert, Laetitia de Kort, Giulio del Popolo, Rita Gobet, Gustav Kiss, Helmut Madersbacher

**Key aspects:** Diagnostics, conservative, minimally invasive and surgical treatment, follow-up

10.00 - 10.30  Coffee break

10.30 - 12.45  **Young talents in Neuro-Urology**  
Seven upcoming talents in the field will present their latest scientific findings and compete for The Swiss Continence Foundation Award of 10’000 Swiss francs.

**Award jury:**  
Emmanuel Chartier-Kastler  
Francisco Cruz  
John P. Heesakkers  
Thomas M. Kessler  
Helmut Madersbacher

12.45 - 13.45  Lunch break
13.45 – 15.45  **Conservative and minimally invasive treatment**  
*Panel:* Francisco Cruz, Stefan de Wachter, Marcus J. Drake, Xavier Gamé, Gilles Karsenty, Jürgen Pannek, Jean-Jacques Wyndaele  

*Key aspects:* Behavioural modification, pharmacotherapy, catheterization, neuromodulation, botulinum toxin

15.45- 16.15  **Tea break**

16.15 - 18.15  **Surgical treatment**  

*Key aspects:* Transurethral procedures, tapes, meshes, prostheses, bladder augmentation, urinary diversions
The Swiss Continence Foundation Award
promoting the next generation in the field

www.swisscontinencefoundation.ch
Scientific programme  I  Friday 29 August 2014  I  NURSING DAY

08.30 – 10.00  Neuro-physiology of lower urinary tract, sexual and bowel (dys)function
Panel: Apostolos Apostolidis, Bertil F. M. Blok, Jean-Jacques Wyndaele

10.00 - 10.30  Coffee break

10.30 - 12.00  Diagnostics in Neuro-Urology
Panel: Daniel Engeler, Enrico Finazzi-Agrò, Philip E. van Kerrebroeck

12.00 - 13.00  Lunch break

13.00 - 15.00  Treatments in Neuro-Urology
Panel: David Castro-Diaz, Giulio del Popolo, Julian Shah

15.00 - 15.30  Tea break

15.30 - 17.30  Catheterization: A major challenge in Neuro-Urology
Panel: Márcio A. Averbeck, Pierre Denys, Jalesh N. Panicker
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Panel or Key Aspects</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 - 13.30</td>
<td><strong>LIVE SURGERY: Robotic cystectomy and open urinary diversion</strong></td>
<td>Daniel Max Schmid, Tullio Sulser</td>
</tr>
<tr>
<td>08.30 – 10.00</td>
<td><strong>Selected neurological diseases</strong></td>
<td>Gérard Amarenco, Pierre Denys, Clare J. Fowler, Gustav Kiss, Jalesh N. Panicker, Jürgen Pannek</td>
</tr>
<tr>
<td></td>
<td><strong>Key aspects:</strong> Multiple sclerosis, Parkinson’s disease, multiple system atrophy, stroke, spina bifida, spinal cord injury, Fowler’s syndrome</td>
<td></td>
</tr>
<tr>
<td>10.00 – 10.30</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>10.30 – 12.30</td>
<td><strong>Case presentations</strong></td>
<td>Márcio A. Averbeck, Pierre Denys, Marcus J. Drake, Helmut Madersbacher, Brigitte Schurch, Karl-Dietrich Sievert, Manfred Stöhrer</td>
</tr>
<tr>
<td>12.30 – 13.30</td>
<td>Lunch break</td>
<td></td>
</tr>
</tbody>
</table>
Scientific programme  |  Saturday 30 August 2014


**Key aspects:** Urinary tract infections, intermittent catheterization, follow-up

15.30 - 16.00  Tea break

16.00 - 18.00  **Jean-Jacques Wyndaele: A milestone in Neuro-Urology**
Panel: Stefan de Wachter, Clare J. Fowler, Helmut Madersbacher, Manfred Stöhrer, Philip E. van Kerrebroeck, Jean-Jacques Wyndaele

18.00 – 18.15  **Conclusions**
Stefan de Wachter, Thomas M. Kessler
CME accreditation

Applications for CME accreditation of this event have been made to the following CME accreditation bodies:

European Accreditation Council for Continuing Medical Education (EACCME®)

Schweizerische Gesellschaft für Allgemeine Innere Medizin (SGIM)

Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe (SGGG)

Schweizerische Gesellschaft für Neurochirurgie (SGNC)

Schweizerische Gesellschaft für Neurorehabilitation (SGNR)

Schweizerische Gesellschaft für Urologie (SGU)

Schweizerische Neurologische Gesellschaft (SNG)
Save the date!

Zürich, Switzerland  
27 – 29 August 2015

4th International NeuroUrology Meeting
Venue details

Venue
Hörsaal Ost B10
University Hospital Zürich
Raemistrasse 100
8091 Zürich
Switzerland
Phone: +41 (0)44 255 11 11

Meeting venue

Lecture halls
OST
PATH
WEST

Entrance
- Main entrance
  Rämistrasse 100
- Emergency entrance
  Schmelzbergstrasse 8
- Delivery entrance
- Entrance north building
  NORD1 Frauenklinikstrasse 10
  NORD2 Frauenklinikstrasse 24
- Side entrance

Coffee bars / restaurants / miscellaneous
- South café
- Dick and Davy coffee bar
- Restaurant
- Main elevators
- Post cash terminal / ATM
- Cash terminal / ATM

Traffic
- Parking area
- Parking deck
- Tram stop ETH/Universitätsspital
- Tram stop Platte
The InterStim® System provides Continuous Control That Moves Patients Forward

Long-Term Control Proven at 5 Years

Directions

By plane: Zürich Airport is one of the most modern airports in Europe. There are regular flights to Zürich from most countries and major cities of the world. From the Airport, you reach the University Hospital Zürich in about 20 minutes by car or by train.

By train: Switzerland has an excellent public transportation system, and there are hourly trains to all major Swiss cities. There are also high-speed and overnight trains to the major cities in Germany, Italy and France.

By car: Zürich has excellent road connections to all major Swiss cities and the surrounding countries. However, we recommend to use public transport if possible as parking spaces are limited.

Public transport in Zürich: Zürich has one of the most efficient public transportation systems in the world. The tram stop „ETH/Universitätsspital“ is right in front of the main entrance of the University Hospital Zürich. Alternatively you can get off at the tram stop „Platte“. The following tram lines will take you there:

From the central station/Bahnhofsstrasse
- No. 6 -> in the direction of Zoo: tram stop ETH/Universitätsspital (3rd stop, 6 minutes) or tram stop Platte (4th stop, 7 minutes)
- No. 10 -> in the direction of Zürich Flughafen: tram stop ETH/Universitätsspital (3rd stop, 6 minutes)

From tram stop Bellevue
- No. 9 -> in the direction of Hirzenbach: tram stop ETH/Universitätsspital (3rd stop, 6 minutes)
- No. 5 -> in the direction of Zoo: tram stop Platte (3rd stop, 5 minutes)
Improve Your Patients’ Pelvic Health with our Innovative line of Products

Cystoscopic Needle for OAB
injeTAK™

Wireless Urodynamics
Aquarius™

Portable 3D Bladder Scanner
BladderVU™

INNOVATION FOR PELVIC HEALTH

LABORIE EUROPE
Lumonics House, Valley Drive,
Swift Valley Industrial Estate
Rugby, Warwickshire, CV21 ITQ  U.K.
Tel.: 44 0 1788 54788

www.LABORIE.com

LABORIE BELGIUM
BC Waasland, Industriepark—West 75
9100 Sint-Niklaas
Belgium
Tel.: 32 3 780 1738
Special events

Gala dinner
(with Swiss Continence Foundation Award ceremony)

Friday 29th August, 19.30
Restaurant Sonnenberg, Hitzigweg 15, 8032 Zürich
Directions with public transport: take the tram lines 3, 8, or 15 to tram stop Klusplatz. From there, just a short walk through the vineyard takes you directly to the restaurant.

Accommodation

Please find a list of partner hotels on our website:
www.swisscontinencefoundation.ch

All partner hotels grant a discount for participants attending the 3rd International Neuro-Urology Meeting.
BJU International is one of the most highly respected medical journals in the world, with a truly international range of published papers and appeal. Every issue gives invaluable practical information in the form of original articles, reviews, comments, Surgical Education articles, and translational science articles in the field of urology. BJU International employs topical sections, and is in full colour, making it easier to browse or search for something specific.

Find out more online at www.bjui.org, or follow us on the following social media sites. 

Try the Anywhere Article version of the Journal articles today! 
Until now, options for downloading and viewing journal research have often been restricted to flat HTML or PDF formats. Wiley’s new enhanced HTML offers a highly interactive and portable alternative.

Go online to try it out today.
Registration

Please register online through our website: www.swisscontinencefoundation.ch

**Attendance fees for online registration until 15th August 2014**

- **Meeting** (including refreshments and lunches) 395 CHF
- **Workshop** (including refreshments and lunch) 100 CHF
  Registration for workshops is only available to participants registered for the 3rd International Neuro-Urology Meeting, limited places available
- **Nursing day** (including refreshments and lunch) 115 CHF
- **Gala dinner** (excluding beverages) 99 CHF

**Attendance fees for online registration after 15th August 2014 or onsite registration**

- **Meeting** (including refreshments and lunches) 495 CHF
- **Workshop** (including refreshments and lunch) 150 CHF
  Registration for workshops is only available to participants registered for the 3rd International Neuro-Urology Meeting, limited places available
- **Nursing day** (including refreshments and lunch) 130 CHF
- **Gala dinner** (excluding beverages) 99 CHF
**Neurogenic Detrusor Overactivity**

2012

**Overactive Bladder**

2013

**Hemifacial Spasm**

1994

**Blepharospasm**

1994

**Cervical Dystonia**

1997

**Primary Axillary Hyperhidrosis**

2003

**Paediatric Cerebral Palsy, dynamic equinus**

1998

**Focal spasticity inclusive upper limb ass. with stroke**

1999

**Primary Axillary Hyperhidrosis**

2003

**Neurogenic Detrusor Overactivity**

2012

**Overactive Bladder**

2013

Abbreviated physician’s information BOTOX® 100 Allergan Units. Composition: Clostridium botulinum type A. Powder for solution for i.m. or i.d. injection. Contains human albumin. Indications: Symptomatic treatment of blepharospasm, hemifacial spasm and associated focal dystonias as well as correction of strabismus in patients > 12 years; cervical dystonia (spasmodic torticollis) in adults; focal spasticity (including spasticity of the upper limb associated with stroke), dynamic equinus foot deformity (without retraction and significant atrophy) in patients ≥ 2 years of age with paediatric cerebral palsy; in adults: primary hyperhidrosis axillae; overactive bladder with symptoms of urinary incontinence, urgency and frequency; the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics; neurogenic detrusor overactivity with urinary incontinence due to subcervical spinal cord injury (traumatic, non-traumatic or multiple sclerosis). Posology: Botulinum toxin units are not interchangeable from one product to another. Administration only by physicians with appropriate qualifications and required experience and equipment (i.e. EMG). Depending on indication and individually, preferably determined by dose titration. Contra-indications: Hypersensitivity to the active substance or to any of the excipients. Infection at proposed inj. sites; contraindications for injections into detrusor: urinary infections, acute urinary retention at the time of treatment, without routinely catheterizing. Warnings/Precautions: Earlier surgical procedures, inj. into vulnerable anatomic structures, inflammation of the proposed inj. site, weakness/atrophy in the target muscle; swallowing, speech or respiratory disorders requiring immediate medical care. Availability of emergency procedures for anaphylactic reactions; reduction of the effectiveness by formation of neutralising antibodies possible. Caution in disorders which may lead to peripheral neuromuscular dysfunction, in patients with subclinical or clinical evidence of defective neuromuscular transmission (e.g. myasthenia gravis or Lambert-Eaton Syndrome), caution when injecting in proximity to the lung (particularly the apices). Use immediately after reconstitution in the syringe (e.g. urinary incontinence). Warning related to indication: www.swissmedicinfo.ch. Interactions: Aminoglycosides, spectinomycin, medicinal products that interfere with neuromuscular transmission, muscle relaxants, other botulinum toxins. No mixture with other medicinal products. Not recommended during pregnancy and in women of childbearing potential not using contraception during pregnancy and breast-feeding. Undesirable effects: (Details for indication related AEs: www.swissmedicinfo.ch). Very common: upper eyelid ptosis, disorders of eye movements, dysphagia, muscle weakness, pain at inj. site, viral infection and ear infection, urinary tract infection, urinary retention. Common: Punctate keratitis, lagophthalmos, dry eye, photophobia, eye irritation/lacrimation increase, eczema, face oedema, inj. site irritations/oedema/bleeding/ hypersensitivity, rhinitis and upper respiratory infection, dizziness, (head) aches, hypoaesthesia, muscle hypertonus, musculoskeletal stiffness and soreness, myalgia, muscle spasms, somnolence, dry mouth, nausea, asthenia, fatigue, influenza-like illness, fever, nervous tremble, gait disturbance, paraesthesia, ophthalmia, urinary incontinence, fall, hot flushes, hyperhidrosis, skin odour abnormal, pruritus, subcutaneous nodule and alopecia, insomnia, constipation, haematuria, dysuria, bladder diverticulum, autonomic dyreflexia, bacteriuria. Uncommon and rare AEs: www.swissmedicinfo.ch. Overdose: Medical monitoring (muscle weakness eventually distant from inj. site, swallow disorders and insufficiency; aspiration pneumonia), ev. hospitalisation required (intubation, assisted breathing). Packages: 1 and 2 x 1 vial containing 100 Allergan Units Botox®. Distribution category: [A]. Reimbursed (depending on indication), Stand of information: December 2013. The complete physician’s information is published on www.swissmedic.ch or www.swissmedicinfo.ch. MAH: Allergan AG, Freienbach, Postadresse: 8808 Pfäffikon SZ. BOTDez13

*Dates represent the first date of approval of this indication in Europe. Please refer to prescribing information below for full indication.*
We thank our sponsors and contributors.